Research explained
CJC-1295 vs Orforglipron: Evidence
CJC-1295 and orforglipron appear together in peptide searches, but they are very different research subjects. CJC-1295 is a growth-hormone-releasing hormone analogue. Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. This distinction matters before comparing any results.
By PurePeptideHub Research Team · Evidence updated
Editorial evidence update; independent clinical review pending. Editorial standards
These publications are not a head-to-head trial. The page compares research designs and does not recommend substituting or combining the substances.
Evidence at a glance
Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.
| Source and design | What it supports | What it cannot establish |
|---|---|---|
| Teichman et al. — CJC-1295 (2006) Two randomized, placebo-controlled, ascending-dose studies in healthy adults. | Measured growth hormone and IGF-1 responses to long-acting CJC-1295. | Hormone changes are not proof of obesity-treatment or muscle-gain outcomes. |
| Wharton et al. — ATTAIN-1 (2025) Phase 3, 72-week placebo-controlled trial in 3,127 adults with obesity without diabetes. | Evaluated weight change with oral orforglipron. | Does not compare orforglipron with CJC-1295. |
What the two studies actually ask
The CJC-1295 publication asks a pharmacology question about hormone responses. ATTAIN-1 asks an obesity-treatment question about body weight. Different questions require different participants and endpoints. Putting their results into one winner-and-loser ranking would hide those differences.
| Feature | CJC-1295 publication | Orforglipron publication |
|---|---|---|
| Research setting | Healthy-adult pharmacology studies | Obesity trial without diabetes |
| Main focus | GH and IGF-1 response | Body-weight change |
| Direct comparison between compounds | No | No |
Sources: Teichman et al. — CJC-1295 (2006) · Wharton et al. — ATTAIN-1 (2025)
Why hormone changes and weight changes cannot be ranked
A laboratory result may help explain a mechanism without proving a clinical benefit. A weight endpoint answers a different question and still needs safety, adherence, and population context. Percentages from different outcome types should not be treated as if they measure the same benefit. Even two weight-loss studies can be difficult to compare when their participants and methods differ.
Check the exact substance and formulation
Names used in product discussions can conceal differences in formulation. The CJC-1295 publication concerns the long-acting compound studied in that paper; it should not be used as a blanket reference for every product marketed with a similar name. Orforglipron should not be described as an injectable peptide simply because it is discussed beside peptide medicines.
Sources: Teichman et al. — CJC-1295 (2006) · Wharton et al. — ATTAIN-1 (2025)
How to use this comparison
Use the original papers to verify the population, route, duration, outcome, and withdrawals behind a claim. A published trial is also distinct from a current prescribing label. This review is an evidence comparison, not a live regulatory-status database. It supplies no conversion, stacking, or treatment-selection protocol.
Common questions
Is orforglipron a peptide?
No. The ATTAIN-1 publication describes it as an oral non-peptide GLP-1 receptor agonist.
Which one is better?
There is no single answer supported by these studies: they address different questions and do not compare the two substances directly.
Can this comparison support using them together?
No. Separate studies of individual substances do not establish the benefit or safety of a combination.
Continue your research
Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.